RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS) on ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

The US Administration for Strategic Preparedness and Response plans to have “up to 10 million doses of prefilled syringes and multidose vials ... Moderna with $176 million to create mRNA ...

Less than a year after China identified the virus, health authorities in the U.S. and Britain cleared vaccines made by Pfizer and Moderna ... but also vials for testing and other supplies ...

At the time of writing, Moderna had not as yet responded to enquiries about its intentions surrounding its Covid-19 vaccine, Spikevax. Join the conversation, on Tuesday 28th January @ 10 am ET - 3 ...

Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine ...